Prolong Pharmaceuticals' PP-007 Receives FDA Breakthrough Therapy Designation for Acute Ischemic Stroke
Prolong Pharmaceuticals has announced that its investigational therapy, PP-007, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS) with Anterior Large Vessel Occlusion. This designation is intended to expedite the development and review of therapies for serious conditions that show substantial improvement over existing treatments. PP-007, also known as PEGylated carboxyhemoglobin bovine, is designed to improve oxygen delivery in ischemic tissue and is currently under evaluation in clinical trials. The therapy has already received Fast Track Designation, highlighting its potential clinical benefits. 
